AIIMS Delhi to begin human trials of India's coronavirus vaccine, Covaxin

Smrithi Mohan
New Update

Among the few institutes selected AIIMS Delhi will begin the testing and clinical trial of Indian's COVID-19 vaccine candidate Covaxin on today(July 20)

India is one of the latest vaccine producers in the world. With the COVID cases increasing day by day, the need for developing a vaccine for the same has become a major priority. India's All India Institute of Medical Sciences (AIIMS) Ethics Committee gave its approval on Saturday to conduct the human clinical trial of the indigenously developed Covid-19 vaccine candidate Covaxin. The hospital started enrolling people who wish to volunteer for the vaccine's testing process.

Phase I and II of the testing for Covaxin will be conducted in 12 selected institutes and AIIMS-Delhi is one among them. According to the reports in phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.

The Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV) has developed Covaxin, which is India's first indigenous Covid-19 vaccine candidate. AIIMS Patna is the first institute where the trial for the testing began on Wednesday along with some other sites. About nine people have been tested there with a smaller dose.

Take a look:

People willing to participate in India's first Covid-19 vaccine trial can send an SMS to or call on 7428847499

Also Read: Russia successfully completes the first-ever Coronavirus vaccine trial

India 2020 coronavirus outbreak coronavirus corona Covid-19 coronavirus airborne coronavirus airborne disease coronavirus airborne guidelines coronavirus vaccine news coronavirus vaccine update AIIMS delhi All India Institute of Medical Sciences (AIIMS) corona in india Covaxin covid vaccine india's covid vaccine india's covid vaccine Covaxin indian vaccine vaccine